JP2015536996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536996A5 JP2015536996A5 JP2015541995A JP2015541995A JP2015536996A5 JP 2015536996 A5 JP2015536996 A5 JP 2015536996A5 JP 2015541995 A JP2015541995 A JP 2015541995A JP 2015541995 A JP2015541995 A JP 2015541995A JP 2015536996 A5 JP2015536996 A5 JP 2015536996A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- patent document
- nanoparticle
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000002105 nanoparticle Substances 0.000 claims 10
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- -1 polyoxyethylene lactic acid copolymer Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 description 5
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical class OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 0 C[n]1c(ccc(N(CCCl)CCCl)c2)c2nc1CCCC(O*)=O Chemical compound C[n]1c(ccc(N(CCCl)CCCl)c2)c2nc1CCCC(O*)=O 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000007884 metabolite profiling Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725213P | 2012-11-12 | 2012-11-12 | |
| US61/725,213 | 2012-11-12 | ||
| US201361776951P | 2013-03-12 | 2013-03-12 | |
| US61/776,951 | 2013-03-12 | ||
| PCT/US2013/069550 WO2014075035A1 (en) | 2012-11-12 | 2013-11-12 | Bendamustine derivatives and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536996A JP2015536996A (ja) | 2015-12-24 |
| JP2015536996A5 true JP2015536996A5 (https=) | 2016-12-28 |
| JP6262246B2 JP6262246B2 (ja) | 2018-01-17 |
Family
ID=49667594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541995A Expired - Fee Related JP6262246B2 (ja) | 2012-11-12 | 2013-11-12 | ベンダムスチン誘導体およびこれを使用する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US9452988B2 (https=) |
| EP (1) | EP2917183A1 (https=) |
| JP (1) | JP6262246B2 (https=) |
| KR (1) | KR20150086308A (https=) |
| AR (1) | AR093457A1 (https=) |
| AU (1) | AU2013342015B2 (https=) |
| BR (1) | BR112015010501A2 (https=) |
| CA (1) | CA2890462A1 (https=) |
| CL (1) | CL2015001246A1 (https=) |
| EA (1) | EA029706B1 (https=) |
| HK (2) | HK1212977A1 (https=) |
| IL (1) | IL238662A (https=) |
| MX (1) | MX2015005805A (https=) |
| PH (1) | PH12015501024A1 (https=) |
| SG (1) | SG11201503560TA (https=) |
| TW (1) | TWI598341B (https=) |
| WO (1) | WO2014075035A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ604708A (en) | 2010-05-20 | 2015-05-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
| BR112015010501A2 (pt) | 2012-11-12 | 2017-07-11 | Ignyta Inc | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada |
| US9598377B2 (en) | 2013-03-12 | 2017-03-21 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| US11071789B2 (en) * | 2016-07-13 | 2021-07-27 | Cephalon, Inc. | Pharmaceutical prodrugs and methods of their preparation and use |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| US12109193B2 (en) | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681964A (en) * | 1990-10-23 | 1997-10-28 | University Of Kentucky Research Foundation | Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US7089218B1 (en) | 2004-01-06 | 2006-08-08 | Neuric Technologies, Llc | Method for inclusion of psychological temperament in an electronic emulation of the human brain |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1343494A4 (en) * | 2000-12-01 | 2005-08-03 | Enzon Inc | PROMOTERS TETRAPARTATES |
| US20060165987A1 (en) * | 2002-04-05 | 2006-07-27 | Patrice Hildgen | Stealthy polymeric biodegradable nanospheres and uses thereof |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
| US8486924B2 (en) | 2007-11-28 | 2013-07-16 | Celator Pharmaceuticals, Inc. | Taxane delivery system |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2326306A1 (en) | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| CA2738855A1 (en) * | 2008-09-29 | 2010-04-01 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| EP2346836B1 (en) | 2008-10-08 | 2018-03-07 | Cephalon, Inc. | Processes for the preparation of bendamustine |
| EP2367542B1 (en) * | 2008-12-03 | 2014-01-01 | Astellas Deutschland GmbH | Oral dosage forms of bendamustine |
| US20130202693A1 (en) | 2010-06-02 | 2013-08-08 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine |
| TWI578997B (zh) | 2010-06-04 | 2017-04-21 | 輝瑞疫苗有限責任公司 | 用於預防或治療菸鹼成癮之共軛體 |
| CN101966158A (zh) | 2010-09-28 | 2011-02-09 | 上海丽思化工科技有限公司 | 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法 |
| US20130217888A1 (en) | 2010-11-01 | 2013-08-22 | Shailpa Medicare Limited | Process for preparing bendamus tine hydrochloride monohydrate |
| DE102010055499A1 (de) | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
| PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| US9308276B2 (en) | 2011-05-17 | 2016-04-12 | University Of South Alabama | Combination therapy for treatment of cancer |
| EP2760842B1 (en) | 2011-09-26 | 2016-11-16 | Fresenius Kabi Oncology Ltd | An improved process for the preparation of bendamustine hydrochloride |
| PT2656843E (pt) | 2012-04-26 | 2015-04-14 | Helmut Schickaneder | Ésteres de bendamustina e compostos relacionados e a sua utilização médica |
| ES2694757T3 (es) | 2012-06-19 | 2018-12-27 | Synbias Pharma Ag | Derivados de bendamustina y compuestos relacionados, y uso médico de los mismos para el tratamiento del cáncer |
| JP2015525799A (ja) | 2012-08-10 | 2015-09-07 | ユニバーシティ・オブ・ノース・テキサス・ヘルス・サイエンス・センターＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ | ターゲティングポリアミノ酸および脂肪酸のコンジュゲートを含む薬物送達ビークル |
| BR112015010501A2 (pt) * | 2012-11-12 | 2017-07-11 | Ignyta Inc | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada |
-
2013
- 2013-11-12 BR BR112015010501A patent/BR112015010501A2/pt not_active IP Right Cessation
- 2013-11-12 SG SG11201503560TA patent/SG11201503560TA/en unknown
- 2013-11-12 US US14/442,088 patent/US9452988B2/en not_active Expired - Fee Related
- 2013-11-12 HK HK16100891.2A patent/HK1212977A1/zh unknown
- 2013-11-12 MX MX2015005805A patent/MX2015005805A/es unknown
- 2013-11-12 AU AU2013342015A patent/AU2013342015B2/en not_active Ceased
- 2013-11-12 CA CA2890462A patent/CA2890462A1/en not_active Abandoned
- 2013-11-12 KR KR1020157015682A patent/KR20150086308A/ko not_active Withdrawn
- 2013-11-12 HK HK16100090.1A patent/HK1215701A1/zh unknown
- 2013-11-12 WO PCT/US2013/069550 patent/WO2014075035A1/en not_active Ceased
- 2013-11-12 EP EP13795940.9A patent/EP2917183A1/en not_active Withdrawn
- 2013-11-12 TW TW102140964A patent/TWI598341B/zh not_active IP Right Cessation
- 2013-11-12 AR ARP130104160A patent/AR093457A1/es unknown
- 2013-11-12 JP JP2015541995A patent/JP6262246B2/ja not_active Expired - Fee Related
- 2013-11-12 EA EA201590925A patent/EA029706B1/ru not_active IP Right Cessation
-
2015
- 2015-04-29 US US14/699,965 patent/US9150517B2/en not_active Expired - Fee Related
- 2015-05-06 IL IL238662A patent/IL238662A/en not_active IP Right Cessation
- 2015-05-07 PH PH12015501024A patent/PH12015501024A1/en unknown
- 2015-05-08 CL CL2015001246A patent/CL2015001246A1/es unknown
- 2015-05-13 US US14/711,747 patent/US9149464B2/en not_active Expired - Fee Related
- 2015-09-28 US US14/868,278 patent/US20160016912A1/en not_active Abandoned
-
2016
- 2016-06-16 US US15/184,968 patent/US9630926B2/en not_active Expired - Fee Related
-
2017
- 2017-03-10 US US15/456,439 patent/US9913827B2/en not_active Expired - Fee Related
-
2018
- 2018-01-24 US US15/879,130 patent/US20180147186A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536996A5 (https=) | ||
| ES2813340T3 (es) | Método de tratamiento del cáncer | |
| Gad et al. | Tolerable levels of nonclinical vehicles and formulations used in studies by multiple routes in multiple species with notes on methods to improve utility | |
| JP5565794B2 (ja) | ピモベンダン及びシクロデキストリンの錯体を含む液体製剤 | |
| Graham-Gurysh et al. | Tumor responsive and tunable polymeric platform for optimized delivery of paclitaxel to treat glioblastoma | |
| ES2860526T3 (es) | Derivados de ciclodextrina eterificada conservados que contienen una composición farmacéutica acuosa líquida | |
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| ES2403413T3 (es) | Manufactura, composiciones y usos del modulador del factor de coagulación Vlla | |
| DK2827863T3 (en) | LIQUID COMPOSITION FOR USE IN A PROCEDURE FOR TREATING BENDAMUSTIN-RESPONSIVE CONDITIONS OF PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION | |
| ES2536177T3 (es) | Formulaciones para la inyección de butanos catecólicos, incluyendo compuestos de NDGA, en animales | |
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2014525449A5 (https=) | ||
| US12403195B2 (en) | Sensitizing cells to proton radiation | |
| Jia et al. | Radioiodine‐131‐Labeled theranostic nanoparticles for transarterial radioembolization and chemoembolization combination therapy of VX2 liver tumor | |
| KR20230116836A (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| RU2647368C2 (ru) | Композиция бендамустина и циклополисахарида | |
| US20210322339A1 (en) | Combination therapy of coenzyme q10 and radiation for treatment of glioma | |
| Lin et al. | Polymer nanoparticles advancements for gynecological cancers | |
| Kutscher et al. | Inhalational Delivery of β‐glucan‐chitosan‐poly (lactic co‐glycolic) acid Nanoparticles Enhance Alveolar Macrophage Rifampin Concentrations for the Treatment of Tuberculosis | |
| CR20210210A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| TW202241415A (zh) | 通路調節劑、含其的醫藥組成物、其用途和採用其的治療方法 | |
| RU2016103098A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| JP2025015727A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤 | |
| JP2009541229A (ja) | 特に局所投与を目的とした注射用医薬組成物 | |
| JP2010502691A (ja) | 抗腫瘍剤を含む水性製剤 |